MannKind (NASDAQ:MNKD) Releases Earnings Results

MannKind (NASDAQ:MNKD) posted its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.05, FiscalAI reports. The business had revenue of $101.87 million during the quarter, compared to the consensus estimate of $107.74 million. The company’s quarterly revenue was up 24.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.03 earnings per share.

Here are the key takeaways from MannKind’s conference call:

• Revenue growth broadened beyond collaborations: Third-quarter revenue rose 24% to $101.9 million, with commercial product revenue roughly doubling to $45 million. Tyvaso DPI royalties increased 12% to $37.5 million, while MannKind said its United Therapeutics agreement is expected to provide more than $1 billion in revenue from 2027 through 2030.
• FUROSCIX ReadyFlow adoption is moving quickly: About 75% of shipments had shifted to ReadyFlow by late October, and the company expects fourth-quarter FUROSCIX sales to roughly match first-half 2026 sales. ReadyFlow’s lower cost of goods could also improve margins as the transition progresses.
• Afrezza’s pediatric launch is gaining traction, but the adult business has underperformed: Pediatric patients now account for about one in four prescriptions, and new-to-brand prescriptions rose nearly 80% sequentially. Management attributed adult weakness partly to reduced promotional support and field-team turnover, and said it plans to refocus resources.
• Management expects a return to profitability: Despite a third-quarter GAAP net loss of $23.2 million, the company expects GAAP and non-GAAP profitability in the fourth quarter and annual profitability in 2027, while continuing to invest in commercial growth.
• Nintedanib DPI advanced, with a longer-term clinical milestone ahead: MannKind reported positive Phase I-B safety and tolerability results and is starting its streamlined Phase II study, with a readout expected in the first half of 2028. The timeline could move faster if the FDA supports adding U.S. sites.

MannKind Trading Up 3.7%

Shares of MNKD traded up $0.14 during midday trading on Friday, hitting $3.90. The stock had a trading volume of 4,984,958 shares, compared to its average volume of 3,481,324. MannKind has a fifty-two week low of $2.23 and a fifty-two week high of $6.51. The business has a 50-day simple moving average of $3.55 and a two-hundred day simple moving average of $3.71. The firm has a market cap of $1.25 billion, a P/E ratio of -16.96 and a beta of 1.10.

More MannKind News

Here are the key news stories impacting MannKind this week:

• Positive Sentiment: Analysts raised price targets. Cantor Fitzgerald lifted its target to $10 from $8 and maintained an “overweight” rating. RBC raised its target to $5 from $4.75, while keeping a “sector perform” rating. Cantor Fitzgerald analyst information RBC price target report
• Positive Sentiment: Longer-term revenue and profitability outlook. MannKind expects its United Therapeutics agreement to generate about $1 billion in revenue from 2027 through 2030, and is targeting profitability in the fourth quarter. United Therapeutics deal and profitability outlook
• Neutral Sentiment: Quarterly results were mixed. MannKind’s revenue rose 24% year over year to $101.87 million, and its reported loss per share was narrower than the consensus estimate. MannKind third-quarter results
• Negative Sentiment: Revenue missed expectations, and the company remained loss-making. Sales of $101.87 million were below analysts’ $107.74 million estimate, while EPS was down from a profit in the year-ago quarter. Q3 loss and revenue miss

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on MNKD shares. Royal Bank Of Canada lifted their price objective on shares of MannKind from $4.75 to $5.00 and gave the company a “sector perform” rating in a research note on Friday. Zacks Research upgraded shares of MannKind from a “strong sell” rating to a “hold” rating in a research report on Monday, October 5th. Chardan Capital initiated coverage on shares of MannKind in a research note on Monday, October 19th. They set a “buy” rating and a $10.00 target price on the stock. HC Wainwright restated a “buy” rating on shares of MannKind in a research report on Thursday, July 23rd. Finally, Cantor Fitzgerald upped their price target on shares of MannKind from $8.00 to $10.00 and gave the stock an “overweight” rating in a research note on Friday. Eight analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $8.33.

Insider Buying and Selling at MannKind

In other news, Director Steven Binder sold 39,051 shares of the business’s stock in a transaction that occurred on Friday, September 25th. The shares were sold at an average price of $3.29, for a total transaction of $128,477.79. Following the sale, the director owned 713,258 shares in the company, valued at $2,346,618.82. The trade was a 5.19% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.60% of the stock is currently owned by company insiders.

MannKind Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF).